Review
Oncology
Yuchen Xie, Songyi Ning, Jianpeng Hu
Summary: This review focuses on the molecular characteristics and relevant genes and molecular mechanisms that contribute to the transformation of neuroendocrine differentiation in prostate cancer, aiming to discover new methods for accurate diagnosis and targeted therapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Review
Cell Biology
Hengfeng Zhou, Qiangrong He, Chao Li, Bassam Lutf Mohammed Alsharafi, Liang Deng, Zhi Long, Yu Gan
Summary: Understanding the role of the tumor microenvironment (TME) in the development and progression of neuroendocrine prostate cancer (NEPC) is crucial for the discovery of new therapies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Medicine, General & Internal
Mallika Marar, Qi Long, Ronac Mamtani, Vivek Narayan, Neha Vapiwala, Ravi B. Parikh
Summary: This study investigated the differences in outcomes between African American and non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC) who received first-line abiraterone therapy. The results showed that African American men had a higher overall survival when receiving first-line abiraterone compared to non-Hispanic White men. However, there was a difference in outcomes between the two groups for first-line enzalutamide treatment.
Review
Biochemistry & Molecular Biology
Tae Jin Kim, Young Hwa Lee, Kyo Chul Koo
Summary: The androgen receptor (AR) plays a crucial role in the development and progression of prostate cancer (PCa), and treatment for hormone-sensitive prostate cancer (HSPC) relies heavily on androgen deprivation therapy (ADT). Despite most patients progressing to castration-resistant prostate cancer (CRPC), studies suggest that manipulating alternative molecular pathways can help improve current treatments and develop novel therapies for CRPC management.
Article
Medicine, General & Internal
Gerhardt Attard, Laura Murphy, Noel W. Clarke, William Cross, Robert J. Jones, Christopher C. Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Claire L. Amos, Nafisah Atako, Cheryl Pugh, Michelle Buckner, Simon Chowdhury, Zafar Malik, J. Martin Russell, Clare Gilson, Hannah Rush, Jo Bowen, Anna Lydon, Ian Pedley, Joe M. O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S. de Bono, David P. Dearnaley, Malcolm D. Mason, Duncan Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise C. Brown, Mahesh K. B. Parmar, Nicholas D. James
Summary: The combination therapy of abiraterone acetate with prednisolone showed significantly higher rates of metastasis-free survival compared with ADT alone in men with high-risk non-metastatic prostate cancer. This combination therapy may be considered a new standard treatment for this patient population.
Article
Pharmacology & Pharmacy
Thomas McKaig, Keiran Logan, Heather Nesbitt, Bridgeen Callan, Stephanie McKeown, Joe M. O'Sullivan, Paul Kelly, Declan O'Rourke, Anthony P. McHale, John F. Callan
Summary: This study investigates the potential of ultrasound targeted microbubble destruction (UTMD) to deliver a combination of docetaxel chemotherapy and Rose Bengal mediated sonodynamic therapy (SDT) in pre-clinical prostate cancer models. The results show that UTMD mediated DTX-MB-RB chemo-sonodynamic therapy is more effective at reducing cell viability compared to UTMD mediated DTX or SDT treatment alone. In both androgen sensitive and androgen resistant prostate cancer models, UTMD mediated DTX-MB-RB therapy is as effective as or even more effective than standard treatments. The DTX dose administered using the DTX-MB-RB formulation is 91% less than standard DTX monotherapy, leading to better tolerability.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2023)
Review
Health Care Sciences & Services
Mayra Alejandra Mafla-Espana, Maria Dolores Torregrosa, Omar Cauli
Summary: Most elderly patients with metastatic prostate cancer should undergo a comprehensive geriatric assessment (CGA) to identify frailty syndrome, which is crucial for clinical decisions. Frailty is associated with lower quality of life and can affect the feasibility and side effects of treatments. Evaluation of frailty syndrome should be considered in clinical decision-making and when selecting the most appropriate active treatment for increased survival.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Fatima Karzai, Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino, Stephanie A. Harmon, David J. VanderWeele, Lisa M. Cordes, Nicole Carrabba, John R. Bright, Nicolas T. Terrigino, Guinevere Chun, Marijo Bilusic, Anna Couvillon, Amy Hankin, Monique N. Williams, Rosina T. Lis, Huihui Ye, Peter L. Choyke, James L. Gulley, Adam G. Sowalsky, Baris Turkbey, Peter A. Pinto, William L. Dahut
Summary: For patients with localized intermediate- or high-risk prostate cancer, baseline mpMRI can help predict pathologic response, with low relative tumor burden at initial scan being most predictive of minimal residual disease or pathologic complete response. Tailoring patient selection based on these metrics may lead to improved outcomes in high-risk disease.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Ulrich Sommer, Tiziana Siciliano, Celina Ebersbach, Alicia-Marie K. Beier, Matthias B. Stope, Korinna Joehrens, Gustavo B. Baretton, Angelika Borkowetz, Christian Thomas, Holger H. H. Erb
Summary: PSMA protein plays an important role in the diagnosis and treatment of prostate cancer, and the activation and inhibition of androgen receptor (AR) can affect PSMA protein levels. This study found that AR activation and inhibition affect PSMA protein levels through a possible non-canonical mechanism, and low PSMA expression rates may be necessary to increase PSMA protein through androgen deprivation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Thi Khanh Le, Quang Hieu Duong, Virginie Baylot, Christelle Fargette, Michael Baboudjian, Laurence Colleaux, David Taieb, Palma Rocchi
Summary: Castration-resistant prostate cancer remains a significant medical challenge, and it is important to understand the underlying mechanisms of resistance and develop new treatment approaches. This review provides an overview of the mechanisms contributing to CRPC progression and discusses current treatment options.
Article
Medicine, General & Internal
Shabbir M. H. Alibhai, Henriette Breunis, Gregory Feng, Narhari Timilshina, Aaron Hansen, Padraig Warde, Richard Gregg, Anthony Joshua, Neil Fleshner, George Tomlinson, Urban Emmenegger
Summary: This study longitudinally examined cognitive function in older men with metastatic castration-resistant prostate cancer undergoing treatment with docetaxel, abiraterone, enzalutamide, and radium Ra 223. The findings suggest that most older men do not experience significant cognitive decline in attention, executive function, and global cognition regardless of the treatment used.
Article
Multidisciplinary Sciences
Sheng-Feng Lin, Hsiu-Chen Lin, Mei-Yu Lee, Joseph Jordan Keller, Li-Hsuan Wang
Summary: This study found a decreased risk of atopic diseases in patients with prostate cancer treated with GnRH analogues. Further studies are warranted to verify the association between testosterone levels and atopic diseases.
Review
Biochemistry & Molecular Biology
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh
Summary: The management of castration-resistant prostate cancer has seen significant progress, with three novel hormonal agents showing survival benefits in non-metastatic patients and a wider range of management options being investigated for metastatic disease.
Review
Multidisciplinary Sciences
Yash B. Shah, Amy L. Shaver, William Kevin Kelly, Grace Lu-Yao
Summary: Abiraterone acetate and enzalutamide are commonly used in prostate cancer therapy, but their toxicities and interactions with patient comorbidities are unclear. Analyzing the differential patient outcomes between these two drugs can provide information for future research and clinical decision-making.
Review
Biochemistry & Molecular Biology
Sooraj Kakkat, Paramahansa Pramanik, Seema Singh, Ajay Pratap Singh, Chandrani Sarkar, Debanjan Chakroborty
Summary: Cardiovascular diseases (CVDs) and complications are commonly observed in patients with prostate cancer (PCa) and can impact their clinical management. Androgen deprivation therapy (ADT), the main treatment for PCa, has been shown to increase cardiovascular risks and metabolic syndromes. There is emerging evidence of a molecular link between PCa and CVDs, but it remains to be fully understood. This article explores the connection between PCa and CVDs, utilizing a comprehensive gene expression study and biological pathway analysis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)